UBT251

People look up UBT251 for weight loss, and most of them found it through retatrutide. It works on the same three signals, it's backed by Novo Nordisk, and its two main trials published their results in October. A lot of the women asking about it have already tried semaglutide or tirzepatide, or followed retatrutide's headlines, and want to know whether this is the next one in line. It has only just started turning up on research vendor sites, so for now the interest runs well ahead of the supply.

The headline comes from a six-month trial in China of 205 adults with overweight or obesity and no diabetes, who started at about 203 pounds on average. Everyone injected once a week, stepping up over the first two to three months to a trial dose or placebo. Here's what each group lost, on average, by week 24:

Source: the published obesity trial in China, October 2026.

Two things stand out. The best result came from a 4 mg schedule, not the top dose, so more wasn't clearly better. And weight was still coming down when the trial stopped, so 24 weeks wasn't the end of the curve. Waist size, blood pressure, cholesterol, triglycerides and blood sugar improved too.

The second trial was in 211 adults with type 2 diabetes, and it put UBT251 up against semaglutide 1 mg, a common Ozempic dose. HbA1c, the three-month average of blood sugar, is the number a diabetes trial lives on.

Source: the published type 2 diabetes trial in China, October 2026. 24 weeks.

Every UBT251 dose beat semaglutide on weight. On blood sugar, only the lowest dose, 2 mg, pulled clearly ahead. Before either one, a smaller 12-week study, the first in people, found that those who finished it on the top dose had lost 15.1% of their weight, per Novo Nordisk.

The people in the obesity trial were in their mid-thirties on average, so these results describe a younger group than most readers of this page.

After a meal, your gut sends out a few hormone signals. GLP-1 tells your brain you've eaten and slows your stomach. GIP helps release insulin and seems to make the GLP-1 side easier to live with. Semaglutide copies the first, tirzepatide copies both, and UBT251, like retatrutide, copies both and adds a third, glucagon, which nudges the body to burn more energy and the liver to burn fat.

Think of the first two as turning down the appetite, and glucagon as turning the furnace up a little. That third signal is the main idea behind triple-signal peptides, and heart rate is one of the things trials of this kind watch closely.

Two things haven't been published. One is its half-life, the time the body takes to clear half a dose, though every trial has dosed it once a week. The other is how strongly it acts on each of the three signals compared with retatrutide. Novo says only that it showed strong activity on all three in lab work, and the comparisons you may see online don't trace back to a source we could read.

UBT251 is an injection under the skin, once a week. There's no label and no dosage page for it yet, so the only amounts with a source are the trial doses. In both published trials, people stepped up over 8 to 12 weeks to 2, 4 or 6 mg a week. One 4 mg group started at 0.5 mg and the other at 1 mg, and the one that started at 1 mg had the best result.

Those are trial doses on the developer's own supply, given to people who were being checked regularly, and nobody has published a different pattern. When there's enough to build a UBT251 dosage page, it'll set out each pattern with its source, the way our retatrutide dosage page does.

The side effects in the obesity trial were the familiar GLP-1 list, mostly mild to moderate and easing over time. Diarrhea was the most common, in about a third of people on UBT251 against 10% on placebo, followed by a reduced appetite, nausea and vomiting. Only one person out of 155 on UBT251 stopped because of side effects, a low number, though it comes from a small, short trial.

Heart rate rose with the dose, by about 10 beats a minute at 6 mg and about 2 at 2 mg. It peaked around week 16 and was back near where it started four weeks after the last injection. In the diabetes trial the rise was smaller, about 4 to 7 beats a minute.

Lipase, a digestive enzyme from the pancreas, was raised in 15% of those on UBT251 against 2% on placebo. Nobody in the trial developed pancreatitis, an inflamed pancreas, but it's the reading a clinician would watch. When researchers scanned a small group's body composition, lean mass, which includes muscle, fell by about 8% to 16%, which is why people on any GLP-1 tend to watch their protein and keep up some strength work.

What nobody knows yet is everything past six months: longer use, heart outcomes, what happens to weight after stopping, and how it behaves in pregnancy. A research vial adds its own question, what's actually in it, which is why an independent lab result for the batch matters more than the label on the box.

UBT251 isn't approved by the FDA or anywhere else. The United Laboratories keeps the rights in mainland China, Hong Kong, Macau and Taiwan, and Novo Nordisk holds them everywhere else after licensing it in March 2025. In the US there's no prescription version, so any UBT251 for sale is sold as a research compound.

It's moving quickly, though. In China, a year-long late-stage obesity trial in 600 people gave its first doses on September 4, 2026, two more in type 2 diabetes started that same month, and two in sleep apnea are registered. Outside China, Novo is running a trial of about 330 people for up to 28 weeks, with results expected in 2027, and started a type 2 diabetes trial in June 2026.

The comparison everyone wants is with retatrutide, the triple-signal peptide from Eli Lilly that's much further along. At the six-month mark their best results look close, but the people in the trials were very different and nobody has tested them side by side. Our news piece on what comes after retatrutide lines the two up and covers the other triple-signal peptides in development.

Tirzepatide is the approved option with two of the three signals, and semaglutide is the one-signal original with the longest track record.

When you compare vendors for any of these, compare the price per milligram rather than the price of one vial, and look for a published lab report for the batch you're buying.

There's no approved UBT251 anywhere, so there's no label to read, and any vial bought online is sold for research.